Search company, investor...

Talima Therapeutics

Founded Year



Unattributed | Alive

Total Raised


Last Raised

$2.82M | 14 yrs ago

About Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Headquarters Location

2255 Martin Avenue Suite F

Santa Clara, California, 95050,

United States


Missing: Talima Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Talima Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Talima Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Talima Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Talima Therapeutics Frequently Asked Questions (FAQ)

  • When was Talima Therapeutics founded?

    Talima Therapeutics was founded in 2004.

  • Where is Talima Therapeutics's headquarters?

    Talima Therapeutics's headquarters is located at 2255 Martin Avenue, Santa Clara.

  • What is Talima Therapeutics's latest funding round?

    Talima Therapeutics's latest funding round is Unattributed.

  • How much did Talima Therapeutics raise?

    Talima Therapeutics raised a total of $21.82M.

  • Who are the investors of Talima Therapeutics?

    Investors of Talima Therapeutics include U.S. Venture Partners, De Novo Ventures, Latterell Venture Partners and Palo Alto Investors.

  • Who are Talima Therapeutics's competitors?

    Competitors of Talima Therapeutics include Brainsgate, Erydel, PolyPid, Veloxis Pharmaceuticals, Savara, Capnia, Transcept Pharmaceuticals, MediQuest Therapeutics, OctoPlus, Medgenics and 19 more.

Compare Talima Therapeutics to Competitors


EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.


Glycologic Limited is a company dedicated to the creation of nutritional, clinical nutrition and drug delivery systems based on carbohydrates which overcome the limitations of other technologies. The Company utilises the properties of carbohydrates to develop customised solutions to a wide variety of nutritional and pharmaceutical problems.

Core Tech Solutions

Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.

Point Biomedical

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphere. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphere, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques.

Selective Amplifier Genes

Selective Amplifier Genes offers artificial genes that improve the functions of vectors for use in blood disorders


BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.